Annual CFO
-$28.57 M
-$29.63 M-2797.45%
31 December 2023
Summary:
Lineage Cell Therapeutics annual cash flow from operations is currently -$28.57 million, with the most recent change of -$29.63 million (-2797.45%) on 31 December 2023. During the last 3 years, it has fallen by -$8.81 million (-44.62%). LCTX annual CFO is now -2797.45% below its all-time high of $1.06 million, reached on 31 December 2022.LCTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$5.79 M
-$611.00 K-11.80%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly cash flow from operations is currently -$5.79 million, with the most recent change of -$611.00 thousand (-11.80%) on 30 September 2024. Over the past year, it has dropped by -$750.00 thousand (-14.89%). LCTX quarterly CFO is now -126.42% below its all-time high of $21.90 million, reached on 31 March 2022.LCTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$22.77 M
-$750.00 K-3.41%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM cash flow from operations is currently -$22.77 million, with the most recent change of -$750.00 thousand (-3.41%) on 30 September 2024. Over the past year, it has increased by +$8.09 million (+26.21%). LCTX TTM CFO is now -494.75% below its all-time high of $5.77 million, reached on 31 March 2022.LCTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2797.4% | -14.9% | +26.2% |
| 3 y3 years | -44.6% | -19.4% | +2.4% |
| 5 y5 years | +7.5% | +22.3% | +29.4% |
LCTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -2797.4% | at low | -126.4% | +48.5% | -494.8% | +29.1% |
| 5 y | 5 years | -2797.4% | +10.6% | -126.4% | +48.5% | -494.8% | +29.4% |
| alltime | all time | -2797.4% | +35.9% | -126.4% | +59.6% | -494.8% | +54.5% |
Lineage Cell Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.79 M(+11.8%) | -$22.77 M(+3.4%) |
| June 2024 | - | -$5.18 M(-10.5%) | -$22.02 M(-4.7%) |
| Mar 2024 | - | -$5.78 M(-3.9%) | -$23.11 M(-19.1%) |
| Dec 2023 | -$28.57 M(-2797.5%) | -$6.02 M(+19.5%) | -$28.57 M(-7.4%) |
| Sept 2023 | - | -$5.04 M(-19.6%) | -$30.85 M(-1.4%) |
| June 2023 | - | -$6.27 M(-44.2%) | -$31.29 M(-2.5%) |
| Mar 2023 | - | -$11.24 M(+35.4%) | -$32.09 M(-3129.9%) |
| Dec 2022 | $1.06 M(-104.5%) | -$8.30 M(+51.5%) | $1.06 M(-69.6%) |
| Sept 2022 | - | -$5.48 M(-22.4%) | $3.49 M(-15.3%) |
| June 2022 | - | -$7.06 M(-132.2%) | $4.12 M(-28.5%) |
| Mar 2022 | - | $21.90 M(-473.0%) | $5.77 M(-124.5%) |
| Dec 2021 | -$23.56 M(+19.3%) | -$5.87 M(+21.1%) | -$23.56 M(+1.0%) |
| Sept 2021 | - | -$4.85 M(-10.5%) | -$23.33 M(+0.0%) |
| June 2021 | - | -$5.42 M(-27.0%) | -$23.33 M(+5.3%) |
| Mar 2021 | - | -$7.42 M(+31.6%) | -$22.15 M(+12.1%) |
| Dec 2020 | -$19.75 M(-38.2%) | -$5.64 M(+16.4%) | -$19.75 M(+0.6%) |
| Sept 2020 | - | -$4.85 M(+14.3%) | -$19.64 M(-11.7%) |
| June 2020 | - | -$4.24 M(-15.7%) | -$22.23 M(-19.6%) |
| Mar 2020 | - | -$5.03 M(-9.0%) | -$27.66 M(-13.4%) |
| Dec 2019 | -$31.95 M(+3.4%) | -$5.52 M(-25.8%) | -$31.95 M(-0.9%) |
| Sept 2019 | - | -$7.44 M(-23.0%) | -$32.24 M(+0.3%) |
| June 2019 | - | -$9.67 M(+3.8%) | -$32.13 M(+7.6%) |
| Mar 2019 | - | -$9.31 M(+60.3%) | -$29.86 M(-3.3%) |
| Dec 2018 | -$30.88 M(+1.2%) | -$5.81 M(-20.7%) | -$30.88 M(+0.4%) |
| Sept 2018 | - | -$7.33 M(-0.9%) | -$30.75 M(-1.1%) |
| June 2018 | - | -$7.40 M(-28.4%) | -$31.09 M(-5.1%) |
| Mar 2018 | - | -$10.34 M(+82.2%) | -$32.76 M(+7.3%) |
| Dec 2017 | -$30.52 M(-27.9%) | -$5.67 M(-26.1%) | -$30.52 M(-9.4%) |
| Sept 2017 | - | -$7.68 M(-15.2%) | -$33.69 M(-3.5%) |
| June 2017 | - | -$9.06 M(+11.9%) | -$34.93 M(-3.3%) |
| Mar 2017 | - | -$8.10 M(-8.5%) | -$36.11 M(-14.7%) |
| Dec 2016 | -$42.33 M(-5.0%) | -$8.85 M(-0.7%) | -$42.33 M(-10.7%) |
| Sept 2016 | - | -$8.91 M(-13.0%) | -$47.42 M(-5.3%) |
| June 2016 | - | -$10.25 M(-28.4%) | -$50.07 M(+0.6%) |
| Mar 2016 | - | -$14.31 M(+2.6%) | -$49.79 M(+11.8%) |
| Dec 2015 | -$44.54 M(+14.6%) | -$13.95 M(+20.6%) | -$44.54 M(+12.2%) |
| Sept 2015 | - | -$11.56 M(+16.0%) | -$39.71 M(+8.0%) |
| June 2015 | - | -$9.97 M(+9.9%) | -$36.76 M(-2.2%) |
| Mar 2015 | - | -$9.07 M(-0.5%) | -$37.57 M(-3.3%) |
| Dec 2014 | -$38.85 M(+31.7%) | -$9.11 M(+5.8%) | -$38.85 M(+1.3%) |
| Sept 2014 | - | -$8.61 M(-20.1%) | -$38.37 M(+6.1%) |
| June 2014 | - | -$10.78 M(+4.1%) | -$36.18 M(+10.2%) |
| Mar 2014 | - | -$10.36 M(+20.1%) | -$32.84 M(+11.3%) |
| Dec 2013 | -$29.51 M(+49.9%) | -$8.63 M(+34.5%) | -$29.51 M(+14.0%) |
| Sept 2013 | - | -$6.42 M(-13.8%) | -$25.88 M(+5.8%) |
| June 2013 | - | -$7.44 M(+6.0%) | -$24.47 M(+16.6%) |
| Mar 2013 | - | -$7.02 M(+40.5%) | -$20.98 M(+6.6%) |
| Dec 2012 | -$19.68 M(+44.8%) | -$5.00 M(-0.3%) | -$19.68 M(+6.2%) |
| Sept 2012 | - | -$5.01 M(+26.6%) | -$18.53 M(+8.3%) |
| June 2012 | - | -$3.96 M(-30.8%) | -$17.12 M(+7.3%) |
| Mar 2012 | - | -$5.72 M(+48.7%) | -$15.95 M(+17.4%) |
| Dec 2011 | -$13.59 M(+75.8%) | -$3.85 M(+7.0%) | -$13.59 M(+8.5%) |
| Sept 2011 | - | -$3.60 M(+28.6%) | -$12.53 M(+14.7%) |
| June 2011 | - | -$2.80 M(-16.7%) | -$10.92 M(+10.7%) |
| Mar 2011 | - | -$3.36 M(+20.9%) | -$9.86 M(+27.6%) |
| Dec 2010 | -$7.73 M(+81.5%) | -$2.78 M(+39.3%) | -$7.73 M(+33.3%) |
| Sept 2010 | - | -$1.99 M(+14.8%) | -$5.80 M(+10.2%) |
| June 2010 | - | -$1.74 M(+41.5%) | -$5.27 M(+18.1%) |
| Mar 2010 | - | -$1.23 M(+45.1%) | -$4.46 M(+4.7%) |
| Dec 2009 | -$4.26 M(+165.5%) | -$845.60 K(-42.0%) | -$4.26 M(+8.5%) |
| Sept 2009 | - | -$1.46 M(+56.6%) | -$3.93 M(+40.9%) |
| June 2009 | - | -$930.70 K(-9.3%) | -$2.79 M(+18.1%) |
| Mar 2009 | - | -$1.03 M(+100.5%) | -$2.36 M(+47.1%) |
| Dec 2008 | -$1.60 M | -$511.70 K(+60.4%) | -$1.60 M(+10.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2008 | - | -$319.10 K(-36.6%) | -$1.45 M(+12.9%) |
| June 2008 | - | -$503.20 K(+86.2%) | -$1.28 M(+13.6%) |
| Mar 2008 | - | -$270.20 K(-23.8%) | -$1.13 M(-9.0%) |
| Dec 2007 | -$1.24 M(-1.8%) | -$354.50 K(+130.9%) | -$1.24 M(+15.3%) |
| Sept 2007 | - | -$153.50 K(-56.1%) | -$1.08 M(-7.3%) |
| June 2007 | - | -$350.00 K(-8.4%) | -$1.16 M(+28.9%) |
| Mar 2007 | - | -$382.00 K(+101.3%) | -$899.40 K(-28.7%) |
| Dec 2006 | -$1.26 M(-10.7%) | -$189.80 K(-20.2%) | -$1.26 M(+74.5%) |
| Sept 2006 | - | -$237.90 K(+165.2%) | -$723.50 K(-36.9%) |
| June 2006 | - | -$89.70 K(-88.0%) | -$1.15 M(-23.6%) |
| Mar 2006 | - | -$744.80 K(-313.5%) | -$1.50 M(+6.1%) |
| Dec 2005 | -$1.41 M(-8.0%) | $348.90 K(-152.8%) | -$1.41 M(-27.9%) |
| Sept 2005 | - | -$660.80 K(+49.1%) | -$1.96 M(+32.3%) |
| June 2005 | - | -$443.20 K(-32.7%) | -$1.48 M(+3.9%) |
| Mar 2005 | - | -$659.00 K(+232.7%) | -$1.43 M(-7.2%) |
| Dec 2004 | -$1.54 M(+134.9%) | -$198.10 K(+8.7%) | -$1.54 M(-14.8%) |
| Sept 2004 | - | -$182.30 K(-52.9%) | -$1.80 M(+65.5%) |
| June 2004 | - | -$387.00 K(-49.7%) | -$1.09 M(+26.3%) |
| Mar 2004 | - | -$769.30 K(+65.7%) | -$862.60 K(+31.9%) |
| Dec 2003 | -$654.10 K(-69.3%) | -$464.40 K(-187.4%) | -$654.20 K(-6.9%) |
| Sept 2003 | - | $531.10 K(-431.9%) | -$702.60 K(-58.6%) |
| June 2003 | - | -$160.00 K(-71.5%) | -$1.70 M(-16.1%) |
| Mar 2003 | - | -$560.90 K(+9.4%) | -$2.02 M(-4.9%) |
| Dec 2002 | -$2.13 M(-33.7%) | -$512.80 K(+10.3%) | -$2.13 M(+12.0%) |
| Sept 2002 | - | -$464.90 K(-4.4%) | -$1.90 M(-25.2%) |
| June 2002 | - | -$486.20 K(-26.9%) | -$2.54 M(-11.2%) |
| Mar 2002 | - | -$665.30 K(+134.3%) | -$2.86 M(-10.8%) |
| Dec 2001 | -$3.21 M(-33.9%) | -$284.00 K(-74.3%) | -$3.21 M(-15.2%) |
| Sept 2001 | - | -$1.11 M(+36.9%) | -$3.78 M(-1.4%) |
| June 2001 | - | -$807.80 K(-20.2%) | -$3.84 M(-10.1%) |
| Mar 2001 | - | -$1.01 M(+17.9%) | -$4.27 M(-12.1%) |
| Dec 2000 | -$4.86 M(+10.5%) | -$858.50 K(-26.1%) | -$4.86 M(-8.2%) |
| Sept 2000 | - | -$1.16 M(-6.3%) | -$5.29 M(+14.3%) |
| June 2000 | - | -$1.24 M(-22.4%) | -$4.63 M(-3.4%) |
| Mar 2000 | - | -$1.60 M(+23.4%) | -$4.79 M(+9.1%) |
| Dec 1999 | -$4.39 M(+109.3%) | -$1.29 M(+159.0%) | -$4.39 M(+41.8%) |
| Sept 1999 | - | -$500.00 K(-64.3%) | -$3.10 M(-18.4%) |
| June 1999 | - | -$1.40 M(+16.7%) | -$3.80 M(+11.8%) |
| Mar 1999 | - | -$1.20 M(0.0%) | -$3.40 M(-26.1%) |
| Dec 1998 | -$2.10 M(-52.3%) | - | - |
| Sept 1998 | - | -$1.20 M(+20.0%) | -$4.60 M(+4.5%) |
| June 1998 | - | -$1.00 M(-16.7%) | -$4.40 M(+51.7%) |
| June 1998 | -$4.40 M(+238.5%) | - | - |
| Mar 1998 | - | -$1.20 M(0.0%) | -$2.90 M(+20.8%) |
| Dec 1997 | - | -$1.20 M(+20.0%) | -$2.40 M(+41.2%) |
| Sept 1997 | - | -$1.00 M(-300.0%) | -$1.70 M(+30.8%) |
| June 1997 | -$1.30 M(-38.1%) | $500.00 K(-171.4%) | -$1.30 M(-27.8%) |
| Mar 1997 | - | -$700.00 K(+40.0%) | -$1.80 M(+63.6%) |
| Dec 1996 | - | -$500.00 K(-16.7%) | -$1.10 M(+83.3%) |
| Sept 1996 | - | -$600.00 K(0.0%) | -$600.00 K(-71.4%) |
| June 1996 | -$2.10 M(+5.0%) | - | - |
| Sept 1995 | - | -$600.00 K(+50.0%) | -$2.10 M(+5.0%) |
| June 1995 | -$2.00 M(+25.0%) | -$400.00 K(-20.0%) | -$2.00 M(-9.1%) |
| Mar 1995 | - | -$500.00 K(-16.7%) | -$2.20 M(+10.0%) |
| Dec 1994 | - | -$600.00 K(+20.0%) | -$2.00 M(+11.1%) |
| Sept 1994 | - | -$500.00 K(-16.7%) | -$1.80 M(+12.5%) |
| June 1994 | -$1.60 M(+23.1%) | -$600.00 K(+100.0%) | -$1.60 M(+14.3%) |
| Mar 1994 | - | -$300.00 K(-25.0%) | -$1.40 M(0.0%) |
| Dec 1993 | - | -$400.00 K(+33.3%) | -$1.40 M(+7.7%) |
| Sept 1993 | - | -$300.00 K(-25.0%) | -$1.30 M(0.0%) |
| June 1993 | -$1.30 M(+116.7%) | -$400.00 K(+33.3%) | -$1.30 M(+44.4%) |
| Mar 1993 | - | -$300.00 K(0.0%) | -$900.00 K(+50.0%) |
| Dec 1992 | - | -$300.00 K(0.0%) | -$600.00 K(+100.0%) |
| Sept 1992 | - | -$300.00 K | -$300.00 K |
| June 1992 | -$600.00 K | - | - |
FAQ
- What is Lineage Cell Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual CFO year-on-year change?
- What is Lineage Cell Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly CFO year-on-year change?
- What is Lineage Cell Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM CFO year-on-year change?
What is Lineage Cell Therapeutics annual cash flow from operations?
The current annual CFO of LCTX is -$28.57 M
What is the all time high annual CFO for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual cash flow from operations is $1.06 M
What is Lineage Cell Therapeutics annual CFO year-on-year change?
Over the past year, LCTX annual cash flow from operations has changed by -$29.63 M (-2797.45%)
What is Lineage Cell Therapeutics quarterly cash flow from operations?
The current quarterly CFO of LCTX is -$5.79 M
What is the all time high quarterly CFO for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly cash flow from operations is $21.90 M
What is Lineage Cell Therapeutics quarterly CFO year-on-year change?
Over the past year, LCTX quarterly cash flow from operations has changed by -$750.00 K (-14.89%)
What is Lineage Cell Therapeutics TTM cash flow from operations?
The current TTM CFO of LCTX is -$22.77 M
What is the all time high TTM CFO for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM cash flow from operations is $5.77 M
What is Lineage Cell Therapeutics TTM CFO year-on-year change?
Over the past year, LCTX TTM cash flow from operations has changed by +$8.09 M (+26.21%)